Cargando…
Adverse events of targeted therapies approved for women's cancers
Breast cancer and gynecologic cancers affect >3 million women worldwide each year. With advances in precision medicine, a growing number of targeted therapies have been approved recently, and new therapeutic classes have emerged, including cell cycle inhibitors for hormone receptor positive breas...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8721120/ https://www.ncbi.nlm.nih.gov/pubmed/35024412 http://dx.doi.org/10.1016/j.ijwd.2021.10.006 |